Liminatus Pharma, Inc. Class A Common Stock
Stock Chart, Company Information, and Scan Results
$0.12(as of Jul 9, 4:00 PM EST)
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Liminatus Pharma, Inc. Class A Common Stock Company Information, Fundamentals, and Technical Indicators
Stock Price$0.12
Ticker SymbolLIMN
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees1
CountyUSA
Market Cap$6.2M
EBIDTA-3.0M
P/E Ratio-0.26
Forward P/E Ratio0.00
Earnings per Share-0.23
Profit Margin-Infinity%
RSI44.88
Shares Outstanding50.6M
ATR0.02
52-Week High9.38
Volume3,313,654
52-Week Low0.10
Book Value-0.1M
P/B Ratio-22.03
Upper Keltner0.17
P/S RatioInfinity
Lower Keltner0.07
Next Earnings DateUnknown
Cash Surplus-1.0M
Next Ex-Dividend DateUnknown
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
Liminatus Pharma, Inc. Class A Common Stock In Our Stock Scanner
As of Jul 10, 2026
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
Scan Name: Mean ReversionScan Type: Stock Indicator Scans
As of ---
Join Our Free Email List
Get emails from us about ways to potentially make money in the stock market.